Process Intensification Program

Mission Statement

The Process Intensification Program accelerates innovative, flexible, and sustainable biopharmaceutical manufacturing by advancing intensified technologies through strong industry–academic collaboration.

Vision Statement

To create a seamlessly integrated, highly intensified, and digitally connected manufacturing ecosystem that enables faster, more reliable, and sustainable delivery of lifechanging therapies.

What Is Process Intensification and How Will It Benefit the Industry?

Process Intensification (PI) is a coordinated approach to biopharmaceutical manufacturing that integrates advanced, scalable technologies and data driven methods to make processes faster, more efficient, and more resilient. The strategy emphasizes end-to-end collaboration across industry, academia, and government to transform how therapies are developed and produced—moving from isolated unit operations to seamlessly integrated, highly intensified, and digitally connected manufacturing systems.

How PI Benefits the Industry

  • Speed to Patients
    Intensified, integrated processes shorten development and manufacturing timelines, helping organizations deliver lifechanging therapies more quickly.
  • Quality & Reliability
    End-to-end control strategies and digital connectivity enhance consistency and real-time decision making, reducing variability and improving product quality.
  • Flexibility & Scalability
    Modular, reconfigurable equipment and software enable rapid adaptation across products and scales—supporting agile responses to changing portfolio needs.
  • Sustainability
    Lifecycle assessment (LCA), process mass intensity (PMI) modeling, and materials innovation help lower environmental impact while maintaining performance.
  • Supply Chain Resilience
    Integrated, intensified operations strengthen robustness and reduce bottlenecks across the value chain.

Process Intensification Program Structure

Workstreams

The PI program is organized into workstreams focused on end-to-end control strategy, equipment flexibility, next generation technology, sustainability, and a physical test bed to evaluate and demonstrate the technologies that are developed. The elements of the program are synergistic.

Next Gen Factory

Identify the technologies and methodologies necessary for the industry to reach the intermediate improvement objectives (3–5 years, second-generation) and breakthrough approaches (third-generation)

Approach
  • Design concepts for second- and third-generation factories and how innovations would have to work together to achieve the vision.
  • Conduct process, operations, and economic modeling of potential new technologies to set the appropriate ambition and show how the vision can be achieved. 
  • Scout and prioritize technology based on results of modeling and conceptual design.
Projects

Next Gen High Level Design of Facility Layout

Next Gen Factory Business & Data Mapping

Economic and Uncertainty Analysis of Manufacturing Operations

Tech Transfer: Analysis of Current Challenges and Defining a Generic Model

Next Gen Factory Vendor Agnostic Equipment User Requirement Specifications

Control Strategy

Explore and address the opportunities and challenges presented by integrated and continuous biomanufacturing processes, with the goal of proposing new control strategies optimized for biological processes of the future.

Approach
  • Robustness: Control strategies for next-generation continuous processes should possess improved risk profiles relative to current control strategies. While the increased interdependencies between unit operations in a continuous process may bring more complexity, they also offer new opportunities for holistic approaches to control, which in turn could lead to increased reliability.
  • Automation and digitalization: A fully connected biologics manufacturing process, in theory, should require reduced manual intervention, but requires increased adoption and greater sophistication of automation and digitalization. This workstream aims to prioritize and then investigate automation strategies that will have the greatest impact on end-to-end control strategies (Feidl et al., 2020).  
  • Integration into process development: Updated control strategies must be accompanied by updated process development methods to ensure that current process development timelines and resource requirements are equivalent or even better for integrated and continuous processes. Because such processes may require longer times between cleaning than their batch counterparts, this will require new and innovative development approaches to bioburden control. 
  • Real-time: Integrated continuous systems present more entry points for real-time or near-real-time process and product monitoring throughout the process flow (cell culture, purification, and formulation). As appropriately capable sensors are developed and tested, and accompanying control loops are designed, process control based on real-time monitoring can be implemented (Patel et al., 2018). Ultimately, this study will culminate in strategies for reduced post-hoc testing for specific attributes and potentially real-time release of drug substance and drug product.
Projects

PI – Rapid Micro: novel methods and control strategy

Working Title: Advancing the Role of Controlled Non‑Classified (CNC) Spaces in Biomanufacturing

Sustainability

Explore how to achieve sustainable, carbon-neutral manufacturing by incorporating sustainability as a design criterion across all areas of bioprocess manufacturing, including raw material sourcing, manufacturing technology R&D, process and facility design, manufacturing operations and waste recycling; also support the development of circular economies for raw materials and consumables using an end-to-end perspective.

Approach
  • Develop decision tools and models that allow process developers to include sustainability — particularly with a goal of low or zero carbon footprint, reduced water and energy use, and reduction and recycling of raw materials
  • Establish practices based on sustainability principles for the selection of raw materials and technologies, design of process and facility, and implementation of manufacturing operations, ensuring sustainability is considered alongside cost, yield, robustness, and quality.
  • Implement a toolbox of options for recycling waste materials, including complex plastics, that supports a circular economy approach and carbon neutral bioprocessing.
Projects

PI – Sustainability Modeling

Working Title: Advancing the Role of Controlled Non‑Classified (CNC) Spaces in Biomanufacturing

Flexibility

Explore strategies for increasing facility and equipment flexibility to address key industry problems, including improvement of demand forecasting and consolidation of products operating at different scales into the same facilities to increase utilization and thus decrease capital and operating cost.

Approach
  • Establish a unified Strategy Playbook that provides a clear understanding of enablers of flexibility and how to apply them most effectively. The playbook will include clear and concise definitions of the goals of the workstream and project roadmaps to achieve them. 
  • Build a Flexibility toolbox to act as a “living document” of available tools to achieve flexibility goals. This toolbox will include a list of prior/ongoing relevant industry initiatives that can avoid redundancies (e.g., BPOG plug-and-play, ISPE Pharma 4.0), libraries of tools (e.g., standards, equipment, components), and software programs, among others.
  • Demonstrate the flexibility solution through a series of interconnected proof-of-concept projects designed to achieve the final vision. These demonstrations are envisioned to be performed in both member institutions and the NIIMBL test bed.
Projects

PI – DNP Development & Adoption

Manufacturing Flexibility Voice-of-Customer Survey

Test Bed

Build a Test Bed at NIIMBL Headquarters in Newark, DE that will run a standard state-of-the-art platform process to produce a non-proprietary monoclonal antibody (cNISTmAb-NIIMBL).

Approach
  • Use the test bed to test new technologies in the context of the entire process and allow comparisons between technologies because they are all evaluated using the same materials.
  • Make process intermediates and drug substance available to technology developers, which will help different labs compare their results for different technologies. This will also save time in the test bed because novel technologies can be developed in labs around the country with representative process inputs and compared with expected outputs.

Progress and updates

High-level program timeline

arrow down
December 2025

Test Bed Demonstration of Operability Complete

July 2025

Sustainability Biosolve Model Webinar

June 2025

Sustainability LCA Model Webinar

March 2024

Flexibility MTP/DNP Workshop

February 2023:

NIIMBL Process Intensification Program (webinar)

November 2022

PI Program Planning Retreat

January 2021

Publication: End-to-end collaboration to transform biopharmaceutical development and manufacturing, Biotechnology and Bioengineering

September 2020

Test Bed Workstream Kickoff

July 2020

Flexibility and Sustainability Workstreams Kickoff

June 2020

Next Gen Factory and Control Strategy Workstreams Kickoff

February 2020

Program Kickoff Workshop

Program publications and outputs

General

Integration – Modeling

Next Generation

Sustainability

Test Bed

User Requirement Specifications (URS)

Program Participants

NIIMBL Program Leader

John Erickson, Senior Fellow

John Erickson

NIIMBL Senior Fellow

Contact

NIIMBL Scientific Project Managers

Melissa Scott, Scientific Program Manager

Melissa Scott

Scientific Project Manager

Contact

Ashley Wang

Scientific Project Manager

Contact

More NIIMBL-led programs

Big Data

The program focuses on five key areas — standardization and contextualization, end-to-end automated control of critical quality attributes (CQAs), multivariate sensors and analytics, advanced control strategies, and bioprocess modeling and simulation – that will enable biomanufacturers to harness the power of data for real-time decision-making.

Preventive Medical Countermeasures

This program brings together stakeholders and resources to collaboratively identify opportunities to advance manufacturing related issues relevant to the development and distribution of vaccines.

Viral Vector

This program’s work aims to establish industrially relevant NIIMBL platform processes for AAV and LV production that could significantly enhance access to and utility of viral vectors for gene-based therapeutic research and development.

Learn more and get involved

NIIMBL members: login for more

To access more program information, including:

  • Program charters
  • Roadmaps and webinars
  • Roster of leadership and participants
  • Program progress reports and workshop results

Not yet a member of NIIMBL?

Learn more about how being a member of NIIMBL can grant you and your company access to NIIMBL-led programs and other collaboration opportunities.